We’ve recently updated our valuation analysis.

Exscientia Valuation

Is EXAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXAI?

Other financial metrics that can be useful for relative valuation.

EXAI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does EXAI's PS Ratio compare to its peers?

The above table shows the PS ratio for EXAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average9.4x
CTIC CTI BioPharma
21.5x46.6%US$705.5m
ADMA ADMA Biologics
5.8x22.7%US$751.3m
CDNA CareDx
2.2x10.0%US$699.2m
AGEN Agenus
8.4x37.2%US$752.9m
EXAI Exscientia
20.6x8.4%US$614.4m

Price-To-Sales vs Peers: EXAI is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (9.4x).


Price to Earnings Ratio vs Industry

How does EXAI's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.1%
n/an/an/a

Price-To-Sales vs Industry: EXAI is expensive based on its Price-To-Sales Ratio (20.6x) compared to the US Biotechs industry average (11.5x)


Price to Sales Ratio vs Fair Ratio

What is EXAI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXAI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.6x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: EXAI is expensive based on its Price-To-Sales Ratio (20.6x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).


Share Price vs Fair Value

What is the Fair Price of EXAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EXAI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EXAI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EXAI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.00
US$14.88
+197.5%
12.5%US$16.87US$11.91n/a4
Dec ’23US$5.77
US$14.88
+157.8%
12.5%US$16.87US$11.91n/a4
Nov ’23US$7.41
US$21.64
+192.0%
44.0%US$38.04US$14.79n/a4
Oct ’23US$8.21
US$21.73
+164.6%
45.0%US$38.59US$15.00n/a4
Sep ’23US$9.89
US$22.78
+130.3%
41.9%US$39.25US$15.90n/a4
Aug ’23US$9.32
US$24.08
+158.4%
34.9%US$38.64US$18.67n/a4
Jul ’23US$11.29
US$24.08
+113.3%
34.9%US$38.64US$18.67n/a4
Jun ’23US$11.70
US$24.94
+113.2%
35.1%US$40.09US$19.32n/a4
May ’23US$10.76
US$25.78
+139.6%
30.9%US$39.46US$19.94n/a4
Apr ’23US$14.93
US$26.74
+79.1%
29.2%US$39.96US$19.65n/a4
Mar ’23US$15.50
US$28.63
+84.7%
25.7%US$39.85US$20.00n/a4
Feb ’23US$18.80
US$28.63
+52.3%
25.7%US$39.85US$20.00n/a4
Jan ’23US$19.76
US$29.93
+51.5%
18.9%US$39.31US$25.00n/a4
Dec ’22US$21.50
US$29.93
+39.2%
18.9%US$39.31US$25.00US$5.774
Nov ’22US$20.75
US$30.42
+46.6%
19.1%US$40.00US$24.90US$7.414

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies